November 2021: Uji klinis pertama dari terapi sel T (CAR-T) reseptor antigen chimeric generasi berikutnya di Korea Selatan, yang dirancang untuk menghindari sinyal pos pemeriksaan kekebalan, baru-baru ini sedang berlangsung.
Korea Advanced Institute of Science and Technology (KAIST) mengumumkan pada hari Rabu bahwa uji klinis Fase 1b dari terapi sel CAR-T saat ini sedang dilakukan di Samsung Medical Center di Seoul. Uji coba sedang dilakukan dengan 10 pasien Korea yang kambuh dan limfoma sel B besar menyebar refrakter. Hak pemasaran untuk pipa dialihkan dari universitas ke perusahaan Curocell, yang didirikan bersama oleh Profesor Kim Chan-hyuk. Curocell bertanggung jawab atas program pengembangan klinis revolusioner imunoterapi.
In addition, a Phase 2 uji klinis involving seventy participants is going to take place the following year to assess how safe and effective the investigational medication is.
The acronym CAR T, which stands for reseptor antigen chimeric T, is frequently referred to as a miracle cure. This is due to the fact that studies conducted in other countries on terminal blood cancer patients demonstrated that the therapy had a therapeutic effect of more than 80 percent. T cells from a patient are taken from the patient’s blood, genetically enhanced to make them more effective, and then reintroduced to the patient so that they can continue to fight and destroy cancer cells inside the patient’s body.
The research team that was led by Professor Kim of the Department of Biomedical Engineering at the KAIST confirmed an improved anticancer efficacy of CAR-T cells in mice with leukaemia and lymphoma. This was achieved by simultaneously inhibiting programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and ITIM domain (TIGIT), both of which are known to disturb the function of T cells. According to Professor Lee Young-ho, a post-doctoral researcher at KAIST and the first author of the animal model study, this dual blockade of PD-1 and TIGIT is a novel strategy to overcome the immunosuppression of existing CAR-T cells. This strategy was discovered by Prof. Lee Young-ho.
Anda mungkin ingin membaca: Terapi Sel T CAR di Korea
Temuan penelitian ini dipresentasikan dalam sebuah artikel yang diterbitkan secara online dalam edisi Oktober Terapi Molekuler.
